Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial
Recent investigation in schizophrenia indicated dehydroepiandrosterone (DHEA) levels to be inversely correlated with extrapyramidal symptomatology (EPS). This study thus investigates the effect of DHEA administration on medication-induced EPS. Inpatients with schizophrenia or schizoaffective disorde...
Gespeichert in:
| Veröffentlicht in: | Schizophrenia research 2005-11, Vol.79 (2), p.251-256 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 256 |
|---|---|
| container_issue | 2 |
| container_start_page | 251 |
| container_title | Schizophrenia research |
| container_volume | 79 |
| creator | Nachshoni, Tali Ebert, Tanya Abramovitch, Yehuda Assael-Amir, Miriam Kotler, Moshe Maayan, Rachel Weizman, Abraham Strous, Rael D. |
| description | Recent investigation in schizophrenia indicated dehydroepiandrosterone (DHEA) levels to be inversely correlated with extrapyramidal symptomatology (EPS). This study thus investigates the effect of DHEA administration on medication-induced EPS. Inpatients with schizophrenia or schizoaffective disorder were randomized in double-blind fashion to receive either 100 mg DHEA or placebo in addition to a constant dosage of antipsychotic medication. Parkinsonism showed a favorable effect of DHEA with a significant time effect (
p
<
0.0001), as well as a significant group by time interaction (
p
<
0.05) and with no change noted on akathisia. Change of DHEA blood levels was negatively associated with change of Parkinsonism (
p
<
0.05) as well as with change of total EPS ratings (
p
<
0.05). DHEA appears to demonstrate a significant effect on EPS, with improvement observed particularly in Parkinsonian symptoms. |
| doi_str_mv | 10.1016/j.schres.2005.07.029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68723375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0920996405002987</els_id><sourcerecordid>68723375</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1f61a54fcae63619802393f7b0f8d7f921343ca58e5e66b7606496499325b3c83</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhSMEokvhHyDkCwgksthx4sQckFal0EqVuMDZcuwJ65VjB9tb2P48fhlT7Uq9cZrLN2_evFdVLxldM8rEh906m22CvG4o7da0X9NGPqpWrOt53XRUPq5WVDa0llK0Z9WznHeUUtbR_ml1xgRrBO-bVfX3el5SvIUZQiFxIvCnJL0ckp6d1Z7kw7yUOGcyRe_jbxd-Egvbg00RFqcDzlwgxQDk7eery807ou3sgssoUlwMxAWiQ3FLPphtLM6QkkAXsAS9u7u44APBabIgjQbyR7IhCWXj7O7Avic27kcP9ehdsGTx2sAYiYmhJLSDKiU57Z9XTybtM7w4zfPqx5fL7xdX9c23r9cXm5vacElLzSbBdNdORoPggsmBNlzyqR_pNNh-kg3jLTe6G6ADIcZeUNFidFLyphu5Gfh59eaoi4H92kMuanbZgPc6QNxnJYa-4bzvEGyPoMF4coJJLcnNOh0Uo-q-O7VTx-7UfXeK9gq7w7VXJ_39OIN9WDqVhcDrE6Cz0X7CpIzLDxwishta5D4dOcA0bh0kvIbxGrAugSnKRvd_J_8AmlW_aQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68723375</pqid></control><display><type>article</type><title>Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Nachshoni, Tali ; Ebert, Tanya ; Abramovitch, Yehuda ; Assael-Amir, Miriam ; Kotler, Moshe ; Maayan, Rachel ; Weizman, Abraham ; Strous, Rael D.</creator><creatorcontrib>Nachshoni, Tali ; Ebert, Tanya ; Abramovitch, Yehuda ; Assael-Amir, Miriam ; Kotler, Moshe ; Maayan, Rachel ; Weizman, Abraham ; Strous, Rael D.</creatorcontrib><description>Recent investigation in schizophrenia indicated dehydroepiandrosterone (DHEA) levels to be inversely correlated with extrapyramidal symptomatology (EPS). This study thus investigates the effect of DHEA administration on medication-induced EPS. Inpatients with schizophrenia or schizoaffective disorder were randomized in double-blind fashion to receive either 100 mg DHEA or placebo in addition to a constant dosage of antipsychotic medication. Parkinsonism showed a favorable effect of DHEA with a significant time effect (
p
<
0.0001), as well as a significant group by time interaction (
p
<
0.05) and with no change noted on akathisia. Change of DHEA blood levels was negatively associated with change of Parkinsonism (
p
<
0.05) as well as with change of total EPS ratings (
p
<
0.05). DHEA appears to demonstrate a significant effect on EPS, with improvement observed particularly in Parkinsonian symptoms.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2005.07.029</identifier><identifier>PMID: 16126372</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Adult and adolescent clinical studies ; Analysis of Variance ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Dehydroepiandrosterone ; Dehydroepiandrosterone - blood ; Dehydroepiandrosterone - therapeutic use ; DHEA ; Double-Blind Method ; EPS ; Extrapyramidal signs ; Female ; Humans ; Hydrocortisone - blood ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Parkinsonism ; Pharmacology. Drug treatments ; Placebos ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychomotor Agitation - etiology ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Psychotic Disorders - blood ; Psychotic Disorders - complications ; Psychotic Disorders - drug therapy ; Schizophrenia ; Schizophrenia - blood ; Schizophrenia - complications ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Schizophrenia research, 2005-11, Vol.79 (2), p.251-256</ispartof><rights>2005 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1f61a54fcae63619802393f7b0f8d7f921343ca58e5e66b7606496499325b3c83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.schres.2005.07.029$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17239584$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16126372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nachshoni, Tali</creatorcontrib><creatorcontrib>Ebert, Tanya</creatorcontrib><creatorcontrib>Abramovitch, Yehuda</creatorcontrib><creatorcontrib>Assael-Amir, Miriam</creatorcontrib><creatorcontrib>Kotler, Moshe</creatorcontrib><creatorcontrib>Maayan, Rachel</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><creatorcontrib>Strous, Rael D.</creatorcontrib><title>Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>Recent investigation in schizophrenia indicated dehydroepiandrosterone (DHEA) levels to be inversely correlated with extrapyramidal symptomatology (EPS). This study thus investigates the effect of DHEA administration on medication-induced EPS. Inpatients with schizophrenia or schizoaffective disorder were randomized in double-blind fashion to receive either 100 mg DHEA or placebo in addition to a constant dosage of antipsychotic medication. Parkinsonism showed a favorable effect of DHEA with a significant time effect (
p
<
0.0001), as well as a significant group by time interaction (
p
<
0.05) and with no change noted on akathisia. Change of DHEA blood levels was negatively associated with change of Parkinsonism (
p
<
0.05) as well as with change of total EPS ratings (
p
<
0.05). DHEA appears to demonstrate a significant effect on EPS, with improvement observed particularly in Parkinsonian symptoms.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Analysis of Variance</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Dehydroepiandrosterone</subject><subject>Dehydroepiandrosterone - blood</subject><subject>Dehydroepiandrosterone - therapeutic use</subject><subject>DHEA</subject><subject>Double-Blind Method</subject><subject>EPS</subject><subject>Extrapyramidal signs</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Parkinsonism</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychomotor Agitation - etiology</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Psychotic Disorders - blood</subject><subject>Psychotic Disorders - complications</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Schizophrenia</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhSMEokvhHyDkCwgksthx4sQckFal0EqVuMDZcuwJ65VjB9tb2P48fhlT7Uq9cZrLN2_evFdVLxldM8rEh906m22CvG4o7da0X9NGPqpWrOt53XRUPq5WVDa0llK0Z9WznHeUUtbR_ml1xgRrBO-bVfX3el5SvIUZQiFxIvCnJL0ckp6d1Z7kw7yUOGcyRe_jbxd-Egvbg00RFqcDzlwgxQDk7eery807ou3sgssoUlwMxAWiQ3FLPphtLM6QkkAXsAS9u7u44APBabIgjQbyR7IhCWXj7O7Avic27kcP9ehdsGTx2sAYiYmhJLSDKiU57Z9XTybtM7w4zfPqx5fL7xdX9c23r9cXm5vacElLzSbBdNdORoPggsmBNlzyqR_pNNh-kg3jLTe6G6ADIcZeUNFidFLyphu5Gfh59eaoi4H92kMuanbZgPc6QNxnJYa-4bzvEGyPoMF4coJJLcnNOh0Uo-q-O7VTx-7UfXeK9gq7w7VXJ_39OIN9WDqVhcDrE6Cz0X7CpIzLDxwishta5D4dOcA0bh0kvIbxGrAugSnKRvd_J_8AmlW_aQ</recordid><startdate>20051115</startdate><enddate>20051115</enddate><creator>Nachshoni, Tali</creator><creator>Ebert, Tanya</creator><creator>Abramovitch, Yehuda</creator><creator>Assael-Amir, Miriam</creator><creator>Kotler, Moshe</creator><creator>Maayan, Rachel</creator><creator>Weizman, Abraham</creator><creator>Strous, Rael D.</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051115</creationdate><title>Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial</title><author>Nachshoni, Tali ; Ebert, Tanya ; Abramovitch, Yehuda ; Assael-Amir, Miriam ; Kotler, Moshe ; Maayan, Rachel ; Weizman, Abraham ; Strous, Rael D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1f61a54fcae63619802393f7b0f8d7f921343ca58e5e66b7606496499325b3c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Analysis of Variance</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Dehydroepiandrosterone</topic><topic>Dehydroepiandrosterone - blood</topic><topic>Dehydroepiandrosterone - therapeutic use</topic><topic>DHEA</topic><topic>Double-Blind Method</topic><topic>EPS</topic><topic>Extrapyramidal signs</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Parkinsonism</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychomotor Agitation - etiology</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Psychotic Disorders - blood</topic><topic>Psychotic Disorders - complications</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Schizophrenia</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nachshoni, Tali</creatorcontrib><creatorcontrib>Ebert, Tanya</creatorcontrib><creatorcontrib>Abramovitch, Yehuda</creatorcontrib><creatorcontrib>Assael-Amir, Miriam</creatorcontrib><creatorcontrib>Kotler, Moshe</creatorcontrib><creatorcontrib>Maayan, Rachel</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><creatorcontrib>Strous, Rael D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nachshoni, Tali</au><au>Ebert, Tanya</au><au>Abramovitch, Yehuda</au><au>Assael-Amir, Miriam</au><au>Kotler, Moshe</au><au>Maayan, Rachel</au><au>Weizman, Abraham</au><au>Strous, Rael D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2005-11-15</date><risdate>2005</risdate><volume>79</volume><issue>2</issue><spage>251</spage><epage>256</epage><pages>251-256</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>Recent investigation in schizophrenia indicated dehydroepiandrosterone (DHEA) levels to be inversely correlated with extrapyramidal symptomatology (EPS). This study thus investigates the effect of DHEA administration on medication-induced EPS. Inpatients with schizophrenia or schizoaffective disorder were randomized in double-blind fashion to receive either 100 mg DHEA or placebo in addition to a constant dosage of antipsychotic medication. Parkinsonism showed a favorable effect of DHEA with a significant time effect (
p
<
0.0001), as well as a significant group by time interaction (
p
<
0.05) and with no change noted on akathisia. Change of DHEA blood levels was negatively associated with change of Parkinsonism (
p
<
0.05) as well as with change of total EPS ratings (
p
<
0.05). DHEA appears to demonstrate a significant effect on EPS, with improvement observed particularly in Parkinsonian symptoms.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16126372</pmid><doi>10.1016/j.schres.2005.07.029</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-9964 |
| ispartof | Schizophrenia research, 2005-11, Vol.79 (2), p.251-256 |
| issn | 0920-9964 1573-2509 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68723375 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Adult and adolescent clinical studies Analysis of Variance Antipsychotic Agents - therapeutic use Biological and medical sciences Dehydroepiandrosterone Dehydroepiandrosterone - blood Dehydroepiandrosterone - therapeutic use DHEA Double-Blind Method EPS Extrapyramidal signs Female Humans Hydrocortisone - blood Male Medical sciences Middle Aged Neuropharmacology Parkinsonism Pharmacology. Drug treatments Placebos Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychomotor Agitation - etiology Psychopathology. Psychiatry Psychopharmacology Psychoses Psychotic Disorders - blood Psychotic Disorders - complications Psychotic Disorders - drug therapy Schizophrenia Schizophrenia - blood Schizophrenia - complications Schizophrenia - drug therapy Schizophrenic Psychology Severity of Illness Index Treatment Outcome |
| title | Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A55%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20extrapyramidal%20symptoms%20following%20dehydroepiandrosterone%20(DHEA)%20administration%20in%20antipsychotic%20treated%20schizophrenia%20patients:%20A%20randomized,%20double-blind%20placebo%20controlled%20trial&rft.jtitle=Schizophrenia%20research&rft.au=Nachshoni,%20Tali&rft.date=2005-11-15&rft.volume=79&rft.issue=2&rft.spage=251&rft.epage=256&rft.pages=251-256&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2005.07.029&rft_dat=%3Cproquest_cross%3E68723375%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68723375&rft_id=info:pmid/16126372&rft_els_id=S0920996405002987&rfr_iscdi=true |